Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.

You may also be interested in...



Supreme Court’s Drug Patent Ruling Could Expand Use Of Expert Testimony

High court rules Federal Circuit should have granted deference to district court’s decision on meaning of a patent claim for a multiple sclerosis drug.

Supreme Court’s Copaxone Ruling Could Increase Expert Witness Testimony

High court rules Federal Circuit should have granted deference to district court’s decision on meaning of Copaxone patent claim; Federal Circuit must now reconsider its finding that the patent is invalid.

Supreme Court Struggles Over What Constitutes A ‘Fact’ In Copaxone Case

Justice Breyer seems to side with Teva’s position that Federal Circuit should have deferred to district court’s finding on meaning of patent term central to Copaxone’s manufacturing process, but other justices appear skeptical.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel